Although studies have demonstrated the significant efficacy of NKG2D CAR-T in the treatment of ovarian cancer [25], triple-negative breast cancer [26], multiple myeloma(MM) [27] and osteosarcoma [28], it is plagued by issues pertaining to limited expansion and persistence [30, 31]. The gene discussed is KLRK1; the disease is triple-negative breast carcinoma.